# US 12,527,852 B2 · Delivery of bacteria-derived outer membrane vesicles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,527,852 B2
- Document ID: US12527852B2
- Status: Granted
- Kind: B2
- Application number: 17/595,330
- Filed: 2020-05-15
- Published: 2022-06-09
- Granted: 2026-01-20
- Earliest claimed: 2019-05-15
- Assignees: Quadram Institute Bioscience
- Applicants: Quadram Institute Bioscience
- Inventors: Simon Carding; Regis Stentz
- Web page: https://patentgrep.com/patent/US12527852B2

## CPC

- A61K 39/0216: {Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/55594: {from bacteria}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Pharmaceutical compositions and preparation including outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier wherein said OMVs are native OMVs produced by the Gram-negative commensal bacteria Bacteroides.

## Claims

### Claim 1

A pharmaceutical preparation comprising outer membrane vesicles (OMVs), at least one additional pharmaceutically active component comprising a vaccine agent, and at least one pharmaceutically acceptable carrier, wherein said OMVs are native OMVs produced by the Gram-negative commensal bacteria Bacteroides, and wherein the OMVs are an adjuvant to reduce the number of doses and/or amount of vaccine agent required to elicit a protective immune response.

### Claim 2 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein the pharmaceutically acceptable carrier is buffered saline.

### Claim 3 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein the preparation is to prevent infection, tumour growth, tissue inflammation and/or injury to the gastrointestinal (GI) and/or respiratory tract and other organ systems.

### Claim 4 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein the pharmaceutical preparation comprises at least two additional pharmaceutically active components.

### Claim 5

A pharmaceutical preparation according to any preceding claim wherein the species of Bacteroides producing the OMVs is B. acidifaciens, B. caccae, B. coprocola, B. coprosuis, B. eggerthii, B. finegoldii, B. fragilis, B. helcogenes, B. intestinalis, B. massiliensis, B. nordii, B. ovatus, B. stercoris, B. thetaiotaomicron, B. vulgatus, B. plebeius, B. uniformis, B. salyersai, B. pyogenes, B. goldsteinii, B. dorei and B. johnsonii and/or B. xylanisolvens.

### Claim 6 (depends on 5)

A pharmaceutical preparation according to claim 5 wherein the B. thetaiotaomicron (Bt) comprises Bt strains VPI-5482, GH193, GH359 and/or GH364.

### Claim 7 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein the at least one additional pharmaceutically active component comprises a Salmonella typhimurium-derived vaccine antigens.

### Claim 8 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein the at least one additional pharmaceutically active component comprises an influenza A virus (IAV) derived vaccine antigens.

### Claim 9 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein the OMV comprises a core stalk region of an influenza A virus (IAV) H5 hemagglutinin from an H5N1 strain.

### Claim 10 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein said pharmaceutical preparation further comprises a heterologous peptide, protein or biologic.

### Claim 11 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein the pharmaceutical preparation is for use in a method for the treatment of typhoid.

### Claim 12 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein the pharmaceutical preparation is for use in a method for the treatment of colitis.

### Claim 13 (depends on 1)

A pharmaceutical preparation according to claim 1 wherein the pharmaceutical preparation is formulated for intranasal administration.